Autophagy inhibition as a potential future targeted therapy for ETV6-RUNX1-driven B-cell precursor acute lymphoblastic leukemia

Translocation t(12;21), resulting in the ETV6-RUNX1 (or TEL-AML1) fusion protein, is present in 25% of pediatric patients with B-cell precursor acute lymphoblastic leukemia and is considered a first hit in leukemogenesis. A targeted therapy approach is not available for children with this subtype of...

Full description

Bibliographic Details

Published in:	Haematologica
Main Authors:	Roel Polak, Marc B. Bierings, Cindy S. van der Leije, Mathijs A. Sanders, Onno Roovers, João R. M. Marchante, Judith M. Boer, Jan J. Cornelissen, Rob Pieters, Monique L. den Boer, Miranda Buitenhuis
Format:	Article
Language:	English
Published:	Ferrata Storti Foundation 2019-04-01
Online Access:	https://haematologica.org/article/view/8848